Genentech Research and Early Development: The Wellspring of Future Therapies

首页> 外文期刊>Science >Genentech Research and Early Development: The Wellspring of Future Therapies

【24h】

Genentech Research and Early Development: The Wellspring of Future Therapies

机译：基因技术研究与早期开发：未来疗法的源泉

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

For more than 30 years, Genentech has been at the forefront of the biotechnology industry, using human genetic information to develop novel medicines for serious and life-threatening diseases. Today, Genentech is among the world's leading biotech companies, with multiple therapies on the market for cancer and other serious medical conditions.

机译：30多年来，Genentech一直处于生物技术行业的最前沿，利用人类遗传信息开发用于治疗严重且威胁生命的疾病的新药。如今，Genentech已跻身于全球领先的生物技术公司之列，在市场上针对癌症和其他严重医疗状况提供多种疗法。

著录项

来源
《Science》 |2009年第5949期|160|共1页
作者

展开▼
作者单位

展开▼
收录信息美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
原文格式 PDF
正文语种 eng
中图分类
关键词
入库时间 2022-08-18 02:54:56

相似文献

外文文献
中文文献
专利

1. Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS) [J] . Paul B Kaplowitz, Dorothy I Shulman, James W Frane, International Journal of Pediatric Endocrinology . 2013,第1期

机译：rhGH治疗过程中第一和第二年生长最好和最差的儿童的特征：Genentech国家合作发展研究（NCGS）25年的数据
2. Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS) [J] . Paul B Kaplowitz, Dorothy I Shulman, James W Frane, International journal of pediatric endocrinology . 2013,第1期

机译：rhGH治疗过程中第一和第二年生长最好和最差的儿童的特征：Genentech国家合作发展研究（NCGS）25年的数据
3. Targeted Radionuclide Therapy: Practical Applications and Future Prospects: Supplementary Issue: Biomarkers and their Essential Role in the Development of Personalised Therapies (A) [J] . Katherine Zukotynski, Hossein Jadvar, Jacek Capala, Biomarkers in Cancer . 2016,第2期

机译：靶向放射性核素治疗：实际应用和未来前景：补充问题：生物标志物及其在个性化疗法发展中的基本作用（A）
4. Present Status and Future Developments in Proton Therapy [C] . Alfred R. Smith International Symposium on Laser-Driven Relativistic Plasmas Applied to Science, Industry and Medicine . 2009

机译：质子疗法的现状和未来发展
5. Development of a Gelfoam-Based Three-Dimensional Culture System to Promote Type II Alveolar Epithelial Cell Maturation for Future Delivery in Cell Therapy [D] . Thanabalasingam, Thenuka. 2021

机译：促进基于Gelfoam的三维培养系统，以促进II型肺泡上皮细胞成熟，以便在细胞疗法中递送
6. Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS) [O] . Paul B Kaplowitz, Dorothy I Shulman, James W Frane, 2013

机译：rhGH治疗过程中第一和第二年生长最好和最差的儿童的特征：Genentech国家合作发展研究（NCGS）25年的数据
7. Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS) [O] . 2013

机译：rhGH治疗期间第一和第二年生长最好和最差的儿童的特征：基因技术国家合作发展研究（NCGS）25年的数据

Genentech Research and Early Development: The Wellspring of Future Therapies

摘要

著录项

相似文献

相关主题

期刊订阅